Clinical TrialsGSK announced its Nucala COPD PIII trial (MATINEE) has met its primary endpoint, with a clinically meaningful and statistically significant reduction in exacerbations vs placebo in patients with baseline eosinophils >300 cells/uL.
Market ExpansionShingrix confirmed broader European rollout progressing well with France the next big opportunity.
OncologyJemperli expansion opportunities into various cancer treatments, potentially tripling the addressable patient pool.